-+ 0.00%
-+ 0.00%
-+ 0.00%
Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger
Share
Listen to the news

Merger with Eos SENOLYTIX expected to close by end of the year

FRAMINGHAM, Mass., Nov. 17, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix", the "Company" or "our") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its third quarter financial results for 2026 and provided a corporate update related to the merger agreement with Eos SENOLYTIX announced at the end of the first quarter of 2026.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending